Parkinson disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) share a-synuclein immunoreactivity. These ''synucleinopathies'' have overlapping signs and symptoms, but less is known about similarities and differences in their cognitive and neuropsychiatric profiles. We compared the cognitive and neuropsychiatric profiles of individuals with PD, MSA, and DLB. Overall, the DLB group showed the most cognitive impairment, the MSA group demonstrated milder impairment, and the PD group was the least cognitively impaired. The DLB and MSA groups showed worse executive function and visuospatial skills than PD, whereas DLB showed impaired memory relative to both PD and MSA. On the neuropsychiatric screening, all groups endorsed depression and anxiety; the DLB group alone endorsed delusions and disinhibition. Consistent with their greater level of cognitive and neuropsychiatric impairment, the DLB group showed the greatest amount of functional impairment on a measure of instrumental activities of daily living (Functional Activities Questionnaire). We found that MSA subjects had cognitive difficulties that fell between the mild deficits of the PD group and the more severe deficits of the DLB group. PD, MSA, and DLB groups have similar neuropsychiatric profiles of increased depression and anxiety. Similar underlying a-synuclein pathology may contribute to these shared features.
P arkinson disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) share overlapping clinical features of parkinsonism and underlying a-synuclein immunoreactivity. 1 Collectively, these diseases are known as the ''synucleinopathies.'' Shared a-synuclein inclusions suggest that modifications in this potentially toxic protein could contribute to disease pathogenesis. Despite their molecular similarities, the synucleinopathies manifest clinically in distinctive ways. Of the 3, PD is felt to be the closest to a pure motor syndrome with the cardinal features of resting tremor, rigidity, and bradykinesia. 2 MSA patients develop early autonomic symptoms, pyramidal signs, and poor response to dopaminergic agents and can be further subdivided into individuals with a preponderance of parkinsonian signs (MSA-P) and those with primarily cerebellar signs (MSA-C). 3 DLB is characterized by fluctuating cognitive impairment, parkinsonian features, and hallucinations. 4 Rapid eye movement (REM) sleep behavior disorder is recognized as being common to all 3 of these synucleinopathies. 5 Multiple factors likely contribute to the differences in clinical symptomatology observed between PD, DLB, and MSA. Despite the fact that PD, DLB, and MSA patients all exhibit a-synuclein pathology in the brain, the regions and structures that are affected vary markedly between the disorders, especially early in disease. In PD, Lewy bodies and neurites are found early in the deep brainstem and substantia nigra. 6 Conversely, paralimbic and neocortical structures are affected early in DLB. 7 Finally, in MSA deep brainstem, cerebellar nuclei as well as striatal and basal ganglia regions show a-synuclein staining. 8, 9 In addition, the primary cell type with a-synuclein immunoreactivity differs between the synucleinopathies. Neurons are affected in PD and DLB, whereas in MSA both neuronal intranuclear inclusions and glial cytoplasmic inclusions are found. 10 As a result of this regional variability, one would expect distinctive patterns of cognitive impairment in the synucleinopathies. Indeed, all 3 have been shown in neuropsychologic batteries to have varying degrees of cognitive dysfunction localized primarily to the executive and visuospatial domains. 11, 12 Recognition of the patterns of cognitive and neuropsychiatric dysfunction in these diseases could contribute to increased diagnostic accuracy and improved targeting of symptoms for treatment.
METHODS

Subjects
Twelve MSA patients were recruited through either the University of California San Francisco Movement Disorders Clinic or the University of California San Francisco Memory and Aging Center from November 2004 to November 2006. They were then matched for age, sex, education, and disease duration (from the time of first motor or cognitive symptom) with 14 PD and 14 DLB patients. A neurologist administered a detailed history and neurologic examination to each subject. At least 2 neurologists reviewed each case to determine whether consensus criteria were met before entry into the study. Probable PD, DLB, or MSA was diagnosed according to established criteria. 3, 4, 13, 14 Informed consent was obtained from all subjects.
Neuropsychologic Testing
General intellectual function was assessed using the Mini-Mental State Examination (MMSE). 15 Tests of executive function include the modified Trails B, a visuomotor set shifting and sequencing task, 16, 17 the Stroop interference task 18 which assesses response inhibition, and trial 1 of the Design Fluency subtest of the Delis-Kaplan Executive Functions Scale. 19 The modified Trails B task required participants to draw lines switching back and forth between numbers and days of the week (ie, 1-Sunday-2-Mondayy) as quickly as possible. 17 Backward digit span was used to assess working memory. Ability to perform 5 written arithmetic calculations was also assessed. The M's and N's task was used to assess perseverative tendencies. 17 Participants were required to write a series of ''m n m ny'' in cursive across an 8.5 Â 11 inch page with the score reflecting the number of perseverations within the series (ie, 0 = none, 1 = perseveration). The California Verbal Learning Test-Short Form 20,21 was used to evaluate verbal episodic memory and a modified (simpler) version of the Rey-Osterrieth complex figure with a 10 minute free-recall delay trial was used to evaluate nonverbal episodic memory. 17 Language assessment included the abbreviated (15 item) Boston Naming Test, 22 repetition, semantic fluency (animals in 1 min), and phonemic fluency (D-words in 1 min). Visuospatial testing included copying the modified Rey-Osterrieth figures and localizing numbers on the visual object and spatial perception battery. 23, 24 Mood was assessed using the Geriatric Depression Scale (GDS). 25 The Functional Activities Questionnaire (FAQ) was used to score degree of independence in activities of daily living 26 and the neuropsychiatric inventory (NPI) was used to assess behavioral and psychiatric symptoms. 27 The FAQ and NPI were completed by the patient's spouse or primary caregiver.
Statistical Analysis
Owing to non-normal distribution of all neuropsychologic variables and small number of subjects, we elected to use nonparametric statistical analysis to compare diagnostic groups. We compared all neuropsychologic variables between groups using Kruskal-Wallis tests. We identified significant group differences, controlling for multiple tests, using the false discovery rate method. 28 Significant group effects were then examined further with posthoc Mann-Whitney U tests. For the NPI, the effect of diagnosis on the presence or absence of symptoms was examined using w 2 tests. Specific statistical results are presented in Tables 1  and 2 .
RESULTS
Demographics
Study subjects were matched for age, sex, education, and disease duration (from first symptom to the time of neuropsychologic evaluation). Subjects were selected with MMSE scores >23 to recruit a DLB cohort with more mild cognitive difficulties. Eleven of the 14 DLB patients met criteria for dementia based on the Diagnostic and Statistical Manual of Mental Disorders Fourth edition (DSM-IV). 29 None of the PD or MSA patients met DSM-IV criteria for dementia. Characteristics of subjects are shown in Table 1 . Ten of 14 PD patients, 2 of 12 MSA patients, and 9 of 14 DLB patients were receiving dopaminergic medications (levodopa and/or a dopamine agonists). One PD and one MSA patient were being treated with a cholinesterase inhibitor, whereas 9 of the DLB patients were treated with this class of medication. Five from each disease grouping were on a selective serotonin reuptake inhibitor. One MSA patient and 3 DLB patients were being treated with an atypical antipsychotic drug. Two PD patients were being treated with anticholinergic agents.
Clinical Neuropsychologic Tests
The means and SDs for results of the cognitive battery administered to subjects are presented in Table 2 and detailed below. A subgroup analysis was performed on MSA subjects and no significant differences were found between those classified as MSA-P (N = 7) versus MSA-C (N = 5) (data not shown).
Executive Function
Across all executive function tasks, the DLB group tended to show the most impairment, the PD group showed the least impairment, and the MSA group fell between DLB and PD subjects. On the modified Trails task, the MSA and DLB subjects took longer to complete the task and made more errors than the PD subjects. For PD patients, there was no significant difference in scores on the modified Trails task between those individuals who were receiving treatment with a dopaminergic agent and those who were not. The DLB subjects showed a reduced number of correct lines relative to the other groups. On a task of design fluency, MSA and DLB subjects both showed a reduction in the number of correct designs relative to PD subjects; however, there was no significant difference in the number of errors between the groups. Although the pattern of DLB<MSA<PD was also apparent on a response inhibition task (Stroop interference), only DLB subjects showed significantly worse performance relative to MSA and PD subjects. Both the MSA and DLB group tended to make more perseverations on the ''m's and n's'' task relative to the PD group. There were no significant group differences on a working memory test (Backward digit span).
Visuospatial Function
On a test of visuospatial abilities, the MSA and DLB group again performed significantly worse than those with PD as evidenced by scores for copying the modified Rey figure. Although DLB subjects had a tendency to perform more poorly than MSA and PD subjects on a spatial location task (visual object and spatial perception battery: number location), this was not significantly different after correction for multiple comparisons.
Language
Consistent with previous reports suggesting only mild language impairment in PD, MSA, and DLB subjects, 30, 31 the groups performed equally well on tests of sentence repetition, object naming (15 item Boston Naming Test), and lexical fluency (D word generation). However, both MSA and DLB groups exhibited decreased semantic fluency (animals generation) compared with PD.
Memory
The California Verbal Learning Test-Short Form was used to assess verbal learning. The DLB group performed worse than PD and MSA groups on ability to encode words over 4 learning trials and also recalled fewer words after 10 minutes. There was also a trend for the DLB subjects to have worse recall at 30 seconds compared with the other groups. Recognition did not differ between the groups for number of words correctly recognized, however, the DLB subjects endorsed more false positives than MSA or PD subjects. There was no statistical difference between groups in visuospatial learning as assessed by recall of the modified Rey figure. In summary, DLB subjects showed relatively greater memory impairment in comparison with MSA and PD subjects, with decreased verbal learning and recall and a tendency to make false positive responses during a recognition task.
Other
On the FAQ, DLB subjects demonstrated the most functional impairment relative to MSA and PD subjects. On the GDS, all groups demonstrated depressive symptoms with no difference between groups.
Neuropsychiatric Symptoms
The prevalence of symptoms from the NPI when administered to subjects' caregivers are presented in Table 3 and detailed below. Overall, DLB showed the most evidence of neuropsychiatric disturbance on the NPI, with the exception of numerically higher rates of anxiety and sleep disturbance in PD subjects. Consistent with the GDS findings, all groups showed high rates of depression; however, there was a trend for depression to be more frequent in PD (87.5%) and DLB (91.7%) relative to MSA (50%). Those with DLB (41.7%) showed significantly higher rates of disinhibition relative to those with MSA (10%) and PD (0%). Only individuals with DLB showed symptoms of delusions (41.7%). Some individuals in all groups had hallucinations. Although these were most frequent in DLB (41.7%), the group differences were not significant (MSA: 20% and PD: 12.5%). Anxiety was quite high across all groups (DLB: 58.3%, MSA: 33.3%, and PD: 62.5%). Other symptoms that were elevated across all groups included agitation, apathy, irritability, repetitive motor behavior, sleep disturbance, and eating changes ( Table 3 ).
DISCUSSION
Differentiation between PD, DLB, and MSA continues to be a problematic diagnostic dilemma. This study compared these groups based upon their neuropsychologic and neuropsychiatric profiles. Overall, on test of cognitive ability, the PD subjects demonstrated the least impairment and the DLB subjects exhibited the most impairment. Despite the perception that MSA tends to spare cognition, the MSA group consistently performed in an intermediate level between the PD and DLB group.
Significant differences between groups were found in tests of executive function. In particular, the DLB and MSA subjects performed worse than PD subjects on tasks that rely heavily on visuospatial processing functions (modified Trails and design fluency). DLB subjects also demonstrated slower processing speed, decreased generation, and increased errors relative to both MSA and PD, consistent with previous research suggesting that DLB subjects show significant impairment in frontal-subcortical executive abilities. 32, 33 Tests of executive function on which there were no significant differences between PD, MSA, and DLB (backward digit span and letter fluency) tended to involve language, rather than visuospatial frontal cortical and subcortical systems.
Results from language testing were notable for relative sparing of sentence repetition and object naming across all groups. However, both DLB and MSA subjects showed decreased semantic fluency relative to PD subjects. Consistent with previous research suggesting that DLB is associated with specific impairment in visuospatial skills, 34 we found that DLB subjects had more difficulty copying a complex figure and on a spatial location task. Again, the MSA group tended to show scores between PD and DLB groups on visuospatial tasks.
Interestingly, some of the most significant cognitive discrepancies were found on tasks of memory. Although all groups demonstrated reductions in visuospatial memory, DLB tended to have the worst performance. In addition, on a verbal learning task, the DLB group had greater impairment both encoding and retrieving information and made more false positive responses on a recognition task. These findings are not unexpected given that Lewy bodies and neurites have been found in the hippocampus at pathology in DLB. 35, 36 Furthermore, Alzheimer disease (AD) and DLB pathology frequently occur together and memory is further impaired in individuals with combined pathology. 34 Not surprisingly, the degree of functional impairment was most severe in DLB and least severe in PD, which is consistent with the higher observed rates of cognitive impairment and of some neuropsychiatric symptoms in DLB.
DLB is known to manifest with neuropsychiatric symptoms, particularly hallucinations and delusions. 4 Depression is associated with PD and DLB. 12 In our study, caregivers reported high rates of depression on the GDS in all 3 groups (PD = 87.5%, MSA = 50%, and DLB = 91.7%). Prominent anxiety was also notable across all groups. Anxiety is known to be found in PD 12, 37 ; we show that it is also seen in MSA and DLB. Although less frequent, other neuropsychiatric symptoms, including apathy, irritability, sleep disturbance, and eating problems were also present among all 3 groups. Although limited by low numbers of subjects, the GDS and NPI results suggest that these a-synuclein disorders share similar neuropsychiatric features, most notably depression and anxiety, which suggests that these symptoms should be monitored and targeted interventions applied when clinically warranted. Future studies are needed to understand whether Results are expressed as percent of subjects that endorsed particular symptoms. Mean total score is expressed as an absolute value out of a total of 144 ± SD.
DLB indicates dementia with Lewy bodies; MSA, multiple system atrophy; NA, not available; PD, Parkinson disease. similar underlying a-synuclein pathology is responsible for the depression and anxiety observed in all 3 groups and how differential pathology may contribute to the hallucinations and delusions of DLB.
Unfortunately, we did not collect Unified Parkinson Disease Rating Scale data for the DLB or MSA patients in our study at the time of enrollment. However, subjects were excluded if the examiner felt the neuropsychologic data collected was unreliable because of motor slowing. The PD patients would be most likely to have lower test scores due to motor impairment. However, on the Trails, Design Fluency, and Rey copy tests, which require relatively more motor coordination, they scored the best compared with other groups. This is consistent with the findings on many of the other tests in which intergroup differences were noted.
Lack of pathologic confirmation of the clinical diagnosis represents a potential limitation of this study. However, we employed the most recent clinical consensus criteria available at the time of the study for each disorder which, in autopsy series, are estimated to have an accuracy of 70% to 95%. 38, 39 New consensus criteria have since been published for MSA. 14 A review of the MSA patients using the new criteria did not result in any change of classification. The most likely confounding factor is the presence of 2 neurodegenerative conditions, such as DLB and AD, occurring simultaneously in the same subject. As concurrent AD would tend to lower MMSE scores, we have tried to minimize this possibility by selecting DLB subjects with relatively high MMSE scores compared with the general population of DLB patients. Nonetheless, pathologic verification of the clinical diagnosis is important for definitive classification of disease characteristics, thus the participants of this study will be followed to autopsy. Additional confounds that could drive intergroup differences include medication treatment (differential use of dopaminergic agents, cholinesterase inhibitors, and antipsychotics), sex, disease duration, and differences in number of patients meeting criteria for dementia based on the DSM-IV. An inability to detect differences between MSA-P and MSA-C subgroups may be due to low numbers of test subjects. Although group differences remained significant after corrections for multiple comparisons, we acknowledge that our sample is small and use of false discovery rate correction can result in Type I error. Thus, our findings deserve additional study and replication.
Despite sharing a-synuclein immunoreactivity in the brain, PD, MSA, and DLB exhibit distinctive profiles of cognitive impairment that may be related to differential regional sensitivity to the toxic effects of a-synuclein or some other factor. Some scientists now believe that formation of pathologic inclusions such as Lewy bodies represents a protective mechanism that cells use to sequester away toxic proteins. 40 Thus, it may be soluble forms of a-synuclein, that are not easily visualized on autopsy samples, are responsible for the differences found in this study. Mutations in a-synuclein are responsible for some forms of familial PD 41 ; whether changes in a-synuclein will be found to causal for sporadic PD, DLB, and MSA remains to be seen. However, their distinctive clinical signs and cognitive profiles in the setting of common a-synuclein immunoreactivity suggest further avenues in which to study the intriguing problem of selective neuronal vulnerability.
